Novartis Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Novartis kazanç ve gelirin sırasıyla yıllık 7% ve 2.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 9.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 37.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

7.0%

Kazanç büyüme oranı

9.1%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.8%
Gelir büyüme oranı	2.1%
Gelecekteki özkaynak getirisi	37.4%
Analist kapsamı	Good
Son güncelleme	07 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

SWX:NOVN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	53,114	13,092	16,857	19,530	13
12/31/2025	52,555	12,383	16,067	18,507	16
12/31/2024	50,551	10,896	14,775	16,979	13
9/30/2024	49,940	11,761	12,552	15,973	N/A
6/30/2024	48,860	10,083	13,560	15,065	N/A
3/31/2024	47,733	9,107	12,071	13,766	N/A
12/31/2023	46,660	8,568	13,660	14,458	N/A
9/30/2023	45,850	7,245	15,507	16,022	N/A
6/30/2023	44,541	7,062	13,241	15,365	N/A
3/31/2023	41,694	5,976	14,009	15,544	N/A
12/31/2022	43,461	6,049	12,167	14,236	N/A
9/30/2022	46,017	21,042	11,545	14,009	N/A
6/30/2022	48,601	22,472	11,714	14,213	N/A
3/31/2022	52,997	24,184	12,349	14,590	N/A
12/31/2021	43,974	22,908	13,201	15,071	N/A
9/30/2021	52,385	9,807	13,015	15,192	N/A
6/30/2021	51,556	8,984	11,222	13,423	N/A
3/31/2021	49,884	7,955	10,699	13,252	N/A
12/31/2020	49,898	8,072	11,445	13,650	N/A
9/30/2020	49,584	7,103	11,743	13,185	N/A
6/30/2020	49,528	7,210	13,255	14,591	N/A
3/31/2020	49,930	7,451	13,077	14,240	N/A
12/31/2019	48,677	7,142	12,341	13,625	N/A
9/30/2019	47,858	7,238	12,122	13,851	N/A
6/30/2019	46,762	7,077	11,477	13,339	N/A
3/31/2019	46,391	12,697	11,778	13,671	N/A
12/31/2018	46,099	12,797	12,447	14,272	N/A
9/30/2018	47,366	13,552	11,748	13,914	N/A
6/30/2018	48,672	13,752	N/A	13,450	N/A
3/31/2018	49,513	8,004	N/A	13,090	N/A
12/31/2017	43,404	7,499	N/A	12,621	N/A
9/30/2017	49,527	6,684	N/A	12,804	N/A
6/30/2017	49,176	6,543	N/A	12,449	N/A
3/31/2017	49,361	6,367	N/A	11,978	N/A
12/31/2016	49,386	6,712	N/A	11,475	N/A
9/30/2016	49,606	6,807	N/A	12,041	N/A
6/30/2016	49,750	6,672	N/A	11,936	N/A
3/31/2016	49,967	6,722	N/A	11,735	N/A
12/31/2015	50,387	7,017	N/A	11,897	N/A
9/30/2015	50,635	8,417	N/A	12,945	N/A
6/30/2015	51,450	9,697	N/A	13,830	N/A
3/31/2015	52,503	10,536	N/A	14,260	N/A
12/31/2014	53,634	10,657	N/A	13,897	N/A
9/30/2014	53,908	10,191	N/A	13,142	N/A
6/30/2014	53,514	9,233	N/A	13,510	N/A
3/31/2014	52,845	9,095	N/A	12,687	N/A
12/31/2013	52,716	9,192	N/A	13,174	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NOVN 'nin tahmini kazanç büyümesi (yıllık 7% ) tasarruf oranının ( 0.3% ) üzerindedir.

Kazançlar ve Piyasa: NOVN şirketinin kazançlarının (yıllık 7% ) Swiss pazarından (yıllık 11.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: NOVN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: NOVN şirketinin gelirinin (yıllık 2.1% ) Swiss pazarından (yıllık 4.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NOVN şirketinin gelirinin (yıllık 2.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NOVN 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 37.4 %)

Novartis Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis AG Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 13%

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Recent updates

New minor risk - Earnings quality

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Upcoming dividend of CHF3.30 per share

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Final dividend of CHF3.30 announced

New minor risk - Earnings quality

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Consensus EPS estimates increase by 13%

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin